Intravacc receives NIH award to develop enterovirus D68 vaccine

By The Science Advisory Board staff writers

September 8, 2020 -- Intravacc has been awarded a $9.4 million contract from the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), to develop a prophylactic vaccine against enterovirus D68 (EV D68).

EV D68 is a respiratory virus that can cause acute flaccid myelitis, a type of childhood paralysis. The company will develop an inactivated EV D68 vaccine, based on its proprietary Vero cell technology, from early product selection through phase I clinical testing.

The Vero cell production platform has been applied for successful production of inactivated poliovirus vaccines, a live attenuated RSV vaccine, and several multivalent vaccines currently under development. The platform is considered safe for the manufacture of human vaccines.

There are currently no effective vaccines or antivirals available and it is anticipated that the virus may cause larger outbreaks in the future. The inactivated EV D68 vaccine developed as part of the contract will undergo first-in-human testing, including virus rescue, assay and process development, preclinical and toxicology studies, and production of clinical trial material.

Intravacc RSV vaccine candidate posts phase I trial results
Intravacc released results of a clinical phase I trial evaluating its live attenuated respiratory syncytial virus (RSV) vaccine candidate.
Intravacc, Celonic to jointly develop COVID-19 vaccine
Vaccine development firm Intravacc and biopharmaceutical contract development and manufacturing organization Celonic are teaming up to develop a COVID-19...
Intravacc, Leiden University explore vaccine quality control without animals
Intravacc has collaborated with the Leiden Academic Center for Drug Research at Leiden University to find alternatives to the use of lab animals in vaccine...
Intravacc, CimCure partner on cancer, COVID-19 vaccines
Intravacc has entered a strategic partnership with CimCure for in-licensing of CimCure's iBoost technology for cancer immunotherapy vaccines and a COVID-19...
Intravacc, Versatope to develop universal flu vaccine
Dutch vaccine developer Intravacc and biotechnology firm Versatope have signed an agreement to collaborate on a universal influenza vaccine.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter